2024 San Antonio Breast Cancer Symposium
The San Antonio Breast Cancer Symposium (SABCS) 2024 highlighted key breast cancer research and treatments. PATINA trial showed Palbociclib improves progression-free survival in HER2-positive metastatic breast cancer. The Lancet Breast Cancer Commission emphasized global inequities and future directions. COMET trial suggested active monitoring for low-risk DCIS is viable. EBCTCG found elevated BMI increases breast cancer recurrence and mortality risks. OlympiA trial demonstrated olaparib's long-term efficacy for BRCA mutation carriers. DECRESCENDO and SUPREMO trials explored less intensive treatment options with promising outcomes.
Reference News
The San Antonio Breast Cancer Symposium (SABCS) 2024 highlighted key breast cancer research and treatments. PATINA trial showed Palbociclib improves progression-free survival in HER2-positive metastatic breast cancer. The Lancet Breast Cancer Commission emphasized global inequities and future directions. COMET trial suggested active monitoring for low-risk DCIS is viable. EBCTCG found elevated BMI increases breast cancer recurrence and mortality risks. OlympiA trial demonstrated olaparib's long-term efficacy for BRCA mutation carriers. DECRESCENDO and SUPREMO trials explored less intensive treatment options with promising outcomes.